Drug Type Small molecule drug |
Synonyms 依奉阿克, CT-1139, TQ B3139 + [1] |
Target |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (11 Jun 2024), |
RegulationSpecial Review Project (CN) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | CN | 11 Jun 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 14 Aug 2019 | |
MET gene amplification Non-small Cell Lung Cancer | Phase 2 | CN | 11 Aug 2020 | |
Non-Small Cell Lung Cancer | Phase 2 | CN | 21 Aug 2019 | |
ALK positive Lung Cancer | Phase 2 | CN | 13 Aug 2019 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 01 Feb 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 01 Feb 2021 | |
Advanced cancer | Phase 1 | CN | 12 Jul 2017 | |
Advanced cancer | Phase 1 | CN | 12 Jul 2017 |
Phase 3 | ALK positive Non-Small Cell Lung Cancer First line | 264 | zumunvciqv(amywhevypv) = mffvmbfuxa aspvjhcwci (qzugwgxbdb ) View more | Positive | 14 Aug 2023 | ||
zumunvciqv(amywhevypv) = yvnzcvzdhy aspvjhcwci (qzugwgxbdb ) View more | |||||||
Phase 3 | ALK positive Non-Small Cell Lung Cancer First line | 264 | Envonalkib 600mg (overall) | hgwwqrhcec(nmnunughwy) = rteuderduh qmktkpolbj (ofmaahovwu ) View more | Superior | 03 Dec 2022 | |
(overall) | hgwwqrhcec(nmnunughwy) = nwcofyiezy qmktkpolbj (ofmaahovwu ) View more | ||||||
Phase 1 | 63 | qfmtejjeuw(gckwlypies) = 76.1% dmefzvoigo (soprxymoac ) View more | Positive | 05 Aug 2022 |